<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362709">
  <stage>Registered</stage>
  <submitdate>3/07/2012</submitdate>
  <approvaldate>3/07/2012</approvaldate>
  <actrnumber>ACTRN12612000709842</actrnumber>
  <trial_identification>
    <studytitle>Seasonal influenza vaccine study to determine the effect of an adjuvanted 2012 influenza vaccine in adults</studytitle>
    <scientifictitle>A randomised controlled trial to evaluate the immune response to an adjuvanted 2012 seasonal trivalent inactivated influenza vaccine in adults</scientifictitle>
    <utrn />
    <trialacronym>FLU006</trialacronym>
    <secondaryid>FLU006</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prevention of influenza infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Other public health</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Single intramuscular immunization with standard 0.5ml dose of commercial 2012 seasonal influenza vaccine alone or combined with Advax(TM) adjuvant administered via either Stratis device or standard pre-filled syringe and needle</interventions>
    <comparator>Commercial 2012 seasonal influenza vaccine</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Serum antibody titers</outcome>
      <timepoint>4 weeks post-immunization</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>B cell response as measured by frequency of memory B cells in the peripheral blood by flow cytometry and ELISPOT analysis</outcome>
      <timepoint>1 week post-immunization</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>T cell response as measured by frequency of memory and effector T cells in the peripheral blood by flow cytomerty and ELISPOT analysis</outcome>
      <timepoint>1,2,3 and 4 weeks post-immunization</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Male or female
Age 18 years or over 
Able to provide written informed consent 
Willing and able to comply with the protocol for the duration of the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>History of vaccination with the 2012 seasonal influenza vaccine
History of serious vaccine or egg allergy
Women of childbearing potential, unless using a reliable and appropriate contraceptive method, specifically oral contraceptive pill, IUD or mechanical barrier device. 
Pregnant or lactating women. 
Receipt of another investigational agent within 14 days preceding initiation of treatment.
Any other serious medical, social or mental condition which, in the opinion of the investigator, would be detrimental to the subjects or the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1 / Phase 2</phase>
    <anticipatedstartdate>1/04/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Vaxine Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Flinders Medical Centre
1 Flinders Drive
Bedford Park
Adelaide 
South Australia
5042</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Vaxine Pty Ltd</fundingname>
      <fundingaddress>Flinders Medical Centre
1 Flinders Drive
Bedford Park
Adelaide 
South Australia
5042</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>Australian Respiratory and Sleep Medicine Institute</sponsorname>
      <sponsoraddress>Flinders Medical Centre
1 Flinders Drive
Bedford Park
Adelaide 
South Australia
5042</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Trial of addition of adjuvant (immune enhancer) to improve effectiveness of seasonal influenza vaccine and trial of Stratis needleless injector device versus standard injection</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Adelaide Clinical Human Research Ethics Committee</ethicname>
      <ethicaddress>Flinders Medical Centre
1 Flinders Drive
Bedford Park
Adelaide 
South Australia
5042</ethicaddress>
      <ethicapprovaldate>23/03/2012</ethicapprovaldate>
      <hrec>59.12</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Nikolai Petrovsky</name>
      <address>Flinders Medical Centre
1 Flinders Drive
Bedford Park
Adelaide 
South Australia
5042</address>
      <phone>+61 8 82044572</phone>
      <fax />
      <email>nikolai.petrovsky@flinders.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dimitar Sajkov</name>
      <address>Flinders Medical Centre
1 Flinders Drive
Bedford Park
Adelaide 
South Australia
5042</address>
      <phone>+61 8 82044572</phone>
      <fax />
      <email>dimitar.sajkov@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Nikolai Petrovsky</name>
      <address>Flinders Medical Centre
1 Flinders Drive
Bedford Park
Adelaide 
South Australia
5042</address>
      <phone>+61 8 82044572</phone>
      <fax />
      <email>nikolai.petrovsky@flinders.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dimitar Sajkov</name>
      <address>Flinders Medical Centre
Flinders Drive
Bedford Park
Adelaide
Australia 5042</address>
      <phone>+61 8 82044572</phone>
      <fax>+61 8 82045987</fax>
      <email>Dimitar.sajkov@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>